Research Reports
Every report we've published, newest first.
HCAI Surges 203% on Nasdaq Extension — A Final Act Before Delisting?
Apr 7, 2026Huachen AI Parking explodes on news it got more time to fix its sub-dollar problem, but this looks like desperation buying on a dilution machine with no real catalyst.
Read → CETXCETX Spikes 125% Pre-Market on Navy SBIR Contract Win
Apr 7, 2026Cemtrex subsidiary Invocon lands Phase I Navy SBIR contract for mine warfare technology, validating the company's aerospace pivot just months after completing its $7.06M acquisition.
Read → FCUVFCUV's 109% Pre-Market Surge: AI Hype Meets Small-Cap Reality Check
Apr 6, 2026Focus Universal rockets 109% pre-market on AI software claims, but traders should watch the float and fundamentals before chasing.
Read → MLECMLEC: The Reverse Split Arithmetic Everyone Missed
Apr 6, 2026While traders chase the 24% pre-market pop, Moolec Science's real story lies buried in complex restructuring mechanics that Wall Street might have miscalculated.
Read → PFSAPFSA: Biotech Dilution Machine Hits the Jackpot with Mayo Clinic Partnership and $30M Acquisition Play
Apr 6, 2026Profusa soars 130% pre-market on PanOmics acquisition and Mayo Clinic partnership, but extreme dilution risk and 377% short interest tell a different story.
Read → TMDETMDE Surges 61% Pre-Market on Iran Crisis — But the IPO Math Tells a Different Story
Apr 2, 2026TMD Energy rocketed in pre-market trading as Middle East tensions spike oil prices, but beneath the geopolitical pop lies a classic post-IPO dilution story with razor-thin margins and troubling cash flow.
Read → BCGBCG: Binah Capital Group's First Profitable Year Masks Real Dilution Concerns
Apr 1, 2026While BCG surged 30% on earnings that showed its first full-year profit as a public company, the celebration might be premature given hidden dilution risks and leverage concerns.
Read → CYCNCYCN Stock Explodes 439% on $380M Korsana Merger - Reverse Takeover Transforms Penny Biotech
Apr 1, 2026CYCN exploded 439% this morning on a $380M reverse merger with Korsana Biosciences, transforming a penny biotech shell into an institutional-backed Alzheimer's drug play.
Read → ARTLARTL Stock Surges 163% as Clinical Expansion into $16.3B Glaucoma Market Demonstrates Platform Power
Mar 27, 2026ARTL exploded 163% overnight as clinical expansion into the $16.3B glaucoma market demonstrates the power of a diversified cannabinoid platform targeting multiple billion-dollar therapeutic verticals.
Read → EEIQEEIQ Stock Explodes 134% as Compliance Mechanics Play Out Perfectly
Mar 26, 2026EEIQ delivered a textbook compliance squeeze, surging 134% on 140x normal volume as the company regained Nasdaq minimum bid requirements just days before their March 2 delisting deadline.
Read → LNAILNAI Rockets 57% on $20M Brain-Delivery Deal as Traders Play Delisting Drama
Mar 26, 2026LNAI explodes 57% on $20M blood-brain barrier acquisition deal as traders position around today's NASDAQ delisting hearing outcome.
Read → RMSGRMSG: 121% Spike Masks Serious Delisting Risk at Real Messenger
Mar 25, 2026Real Messenger's massive Monday surge looks like classic penny stock manipulation as the company faces Nasdaq delisting after falling below $1 for 30 straight days.
Read →